Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
211
-
Total 13F shares, excl. options
-
74.2M
-
Shares change
-
+771K
-
Total reported value, excl. options
-
$2.89B
-
Value change
-
+$26.5M
-
Put/Call ratio
-
1.02
-
Number of buys
-
96
-
Number of sells
-
-97
-
Price
-
$38.99
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2024
246 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q2 2024.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 211 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74.2M shares
of 77.3M outstanding shares and own 95.9% of the company stock.
Largest 10 shareholders include FMR LLC (6.77M shares), Avoro Capital Advisors LLC (5.67M shares), Driehaus Capital Management LLC (4.42M shares), WELLINGTON MANAGEMENT GROUP LLP (3.83M shares), COMMODORE CAPITAL LP (2.75M shares), Capital World Investors (2.68M shares), BRAIDWELL LP (2.56M shares), Polar Capital Holdings Plc (2.54M shares), Capital International Investors (2.48M shares), and BlackRock Inc. (2.1M shares).
This table shows the top 211 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.